Nutra Pharma Corp., a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its drug discovery division, ReceptoPharm, is expanding the clinical research of its lead antiviral drug candidate, RPI-MN, into South America. RPI-MN was used in early clinical studies in Mexico and Peru.
“With the initiation of the neurological program, we are now focusing on advancing our antiviral program.” explained Paul Reid, CEO of ReceptoPharm, Inc. “We have initiated discussions with motivated investigators in South America with the aim of conducting two Phase II antiviral trials, aimed to start in the 2nd and 3rd quarters of 2007, each with a primary duration of 3-4 months,” he added.
RPI-MN is ReceptoPharm’s lead drug candidate for the treatment of viral infections, such as the Herpes Simplex Virus (HSV) and HIV/AIDS. According to the Centers for Disease Control and Prevention (CDC), at least 45 million people ages 12 and older have had genital HSV infection and over 1 million people in the United States are infected with HIV. Currently there is no cure for either disease.
“Conducting Phase II trials utilizing accepted FDA and International guidelines in South America can provide advantages to ReceptoPharm that would otherwise be unavailable in the United States,” commented Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “In addition to having better access to patients, South American trials are often much less expensive and can be conducted within a shorter time-frame,” he concluded.
In January, ReceptoPharm announced positive results of its series of microarray studies with RPI-MN in healthy immune cells. Based upon the results of these studies, RPI-MN could conceivably be used to protect against contagious viral diseases when vaccines are not readily available.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The expansion of clinical research into South America should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.